- Home
- SPT vs OCUL Comparison
SPT vs OCUL Comparison
Compare SPT & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPT | OCUL |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 633.9M | 3.4B |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SPT | OCUL |
|---|---|---|
| Price | $11.45 | $12.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $26.00 | $22.56 |
| AVG Volume (30 Days) | 1.0M | ★ 3.9M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $443,750,000.00 | $55,783,000.00 |
| Revenue This Year | $13.30 | N/A |
| Revenue Next Year | $11.37 | $11.96 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.09 | N/A |
| 52 Week Low | $9.16 | $5.79 |
| 52 Week High | $35.18 | $16.44 |
Technical Indicators
Market Signals| Indicator | SPT | OCUL |
|---|---|---|
| Relative Strength Index (RSI) | 59.12 | 43.14 |
| Support Level | $10.97 | $12.27 |
| Resistance Level | $12.06 | $13.06 |
| Average True Range (ATR) | 0.45 | 0.65 |
| MACD | 0.04 | -0.27 |
| Stochastic Oscillator | 62.62 | 0.13 |
Price Performance
Historical ComparisonAbout SPT Sprout Social Inc
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions.
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.